A utoimmune type 1 diabetes is a chronic, complex autoimmune disease mediated by the infiltration of autoreactive lymphocytes into the pancreas, resulting in the destruction of the insulin-producing ␤-cells in the islets of Langerhans (1) . The nonobese diabetic (NOD) mouse is a spontaneous murine model of type 1 diabetes and involves many of the same autoantigens targeted by human T-cells (1) (2) (3) (4) (5) . CD4 ϩ T-cells appear to be essential in both the early and late stages of the disease, as evidenced by the ability of multiple CD4
ϩ T-cell clones to transfer disease (6 -8) . Additionally, anti-CD4 therapy can prevent the onset of disease in NOD mice (9) .
Over two dozen islet specific autoantigens have been implicated in the initiation and/or pathogenesis of diabetes (6) . While T-cell responses to many of these antigens have been studied (e.g., GAD [10 -13] , insulin [14, 15] , the tyrosine phosphatase-like protein insulinoma-associated protein 2 (IA2) [islet cell antigen 512] [16 -18] , and IA2␤
[phogrin] [19, 20] ), their relative contribution to disease initiation or pathogenesis remains unclear. Furthermore, the specificities of the majority of diabetogenic T-cell clones isolated from NOD mice are still unknown (8) . A key question that remains unresolved is the extent to which autoantigenicity and pathogenicity are linked.
The hallmark of preclinical type 1 diabetes is the infiltration of CD4 ϩ T-cells into the pancreatic islets. While many cell types participate in the disease process, CD4 ϩ T-cells command a central role in the initiation, regulation, and progression of the disease. Clearly autoantigen specificity plays a critical role in governing CD4 ϩ T-cell entry into islets. However, the ability to study these processes using unmanipulated T-cell populations that have a broad range of insulitic and diabetogenic potential has been greatly limited. T-cell receptor (TCR) transgenic (Tg) mice are powerful tools for the analysis of autoimmune diseases such as type 1 diabetes. However, only five major histocompatibility complex class II-restricted, autoantigenspecific Tg NOD lines have been described (BDC-2.5, BDC-6.9, NY4.112-4.1, and a GAD 286 -300 Tg), providing a limited phenotypic range (21) (22) (23) (24) (25) . We developed a new approach for the rapid generation of TCR Tg mice, refered to as retrogenic (Rg) mice, using retroviral-mediated stem cell gene transfer and novel self-cleaving 2A peptidelinked multicistronic retroviral vectors that express both TCR chains plus a fluorescent protein marker in a single vector (26 -30) . This approach allows us to generate and analyze multiple TCR Rg mice on a variety of defined genetic backgrounds in less than 2 months. This is partic-ularly important in studying diabetes, for which background genes have a significant effect on disease outcome (31). Furthermore, the phenotype of Tg mice can be affected by additional variables such as the level and timing of TCR expression and the possibility of insertional mutagenesis by the integrated transgene. These issues are eliminated in Rg mice because the same expression system is used for all TCRs; multiple, independently generated mice are analyzed; and retroviral integration is widespread. This facilitates the direct comparison between multiple TCRs.
The goal of this study was to assess the link between autoreactivity versus pathogenicity of multiple autoantigen-specific TCRs using the Rg system. We chose to clone and generate a panel of Rg mice expressing twelve different TCRs specific for four known autoantigens (various epitopes of GAD65, IA2, phogrin, and insulin) and four different TCRs specific for unknown islet antigens. All four known autoantigens have been implicated in the disease onset, but their relative contribution is still controversial. With this panel of Rg mice, we addressed two important questions. First, are all autoreactive TCRs pathogenic and capable of initiating insulitis and diabetes in the absence of other T-cells and B-cells? Second, is there a defined relationship between the extent of insulitis, the time of diabetes onset, and the incidence of diabetes?
RESEARCH DESIGN AND METHODS
NOD.scid mice were obtained from The Jackson Laboratory and bred in-house. B6.H2 g7 mice were provided by Christophe Benoist and Diane Mathis (Joslin Diabetes Center, Boston, MA) (31) and crossed onto an RAG-1 Ϫ/Ϫ background. Diabetes incidence was monitored on a biweekly, weekly, or more frequent basis by testing for the presence of glucose in the urine by Clinistix (Bayer, Elkhart, IN). Mice testing positive by Clinistix were then tested with a One Touch Ultra glucometer (Lifescan, Milpitas, CA) for blood glucose levels and were considered diabetic if their blood glucose was Ͼ200 mg/dl for retroviral-mediated stem cell gene transfers or 400 mg/dl for adoptive transfers. All mice were bred and housed at the St. Jude Animal Resources Center (Memphis, TN) in a Helicobacter-free specific pathogen free facility following state, national, and institutional mandates. The St. Jude Animal Resources Center is accredited by the American Association for the Accreditation of Laboratory Animal Care. All animal experiments followed animal protocols approved by the St. Jude institutional animal care and use committee. TCR retroviral constructs. All TCRs were generated as 2A-linked single open reading frame inserts using RT-PCR and cloned into a murine stem cell virus-based retroviral vector with a green fluorescent protein (GFP) marker as previously described (26,28 -30) . Details of cloning strategies and primer sequences are available on request (amanda.burton@stjude.org). TCRs were cloned by PCR using plasmid or cDNA obtained from Phogrin13 and Phogrin18 T-cell clones; 10.23 hybridoma from John Hutton (Barbara Davis Center for Diabetes, Aurora, CO); BDC-6.9 and BDC-10.1 T-cell clones from Kathryn Haskins (University of Colorado Health Sciences Center, Denver, CO); BDC-2.5 TCR plasmids from Luc Teyton (Scripps Research Institute, La Jolla, CA); NY4.1 TCR plasmids from Pere Santamaria (University of Calgary, Alberta, Canada); 1A4 TCR plasmids from Roland Tisch (University of North Carolina, Chapel Hill, NC); 530.45.19 hybrid from Eli Sercarz (Torrey Pines Institute for Molecular Studies, San Diego, CA); and PA15.14B12, PA19.5E11, PA18.10F10, PA17.9G7, PA18.9H7 and PA21.14H4 hybridomas generated in our lab by Paula Arnold. The 12-4.4 v1 and 12-4.1 TCR constructs were generated de novo from the published sequence data (12-4.1 accession numbers: DQ172905 for ␣-chain and DQ180320 for ␤-chain) and information generously provided by George Eisenbarth (Barbara Davis Center for Childhood Diabetes). For TCR with unknown V␣ and V␤ usage, V␤ was determined by flow cytometry using V␤-biotinylated antibodies and streptavidin phycoerythrin (PE). V␣ usage was determined by RT-PCR with V␣ primers, cloning into the PCR Blunt II-TOPO vector (Invitrogen, Carlsbad, CA), and sequencing as previously described (32) . All TCR 2A-linked vectors utilize the PTV1.2A sequence except for PA21.14H4, NY4.1, and PA18.10F10, which utilize the TaV.2A sequence (27, 28) . The BDC-10.1 and BDC-6.9 vectors contain a gly-ser-gly linker between the C␣ region and the PTV1.2A sequences. The BDC-2.5 vector lacks this linker, while the remaining vectors contain a gly between the C␣ region and the 2A sequences. Retroviral-mediated stem cell gene transfer, flow cytometric analysis, and cell sorting. Retroviral-mediated stem cell gene transfer was performed as previously described (26 -30 , IN) , harvested, and placed in 3-5 ml collagenase P on ice. The pancreata were then incubated at 37°C for 16 -20 min, after which 7 ml Hanks' balanced salt solution (HBSS) with 5% fetal bovine serum (FBS) was added and the tissues pelleted at 1,000 rpm for 3 min. The pellet was washed twice with 7 ml 5% FBS/HBSS and resuspended in 7 ml 5% FBS/HBSS. Islets were handpicked and dissociated with 1 ml cell dissociation buffer (Invitrogen, Carlsbad, CA) and incubated at 37°C for 5 min. After vortexing, the dissociation process was repeated twice. Cells were placed in 10 ml 5% FBS/HBSS, centrifuged for 10 min at 1,300 rpm, resuspended in 5% FBS/HBSS, and irradiated at 3,000 rads. Functional assays. To Insulitis scores. Pancreata of NOD.scid TCR retrogenic mice were harvested at 28, 70, and 140 days posttransplant; placed into 10% buffered formalin; and embedded in paraffin; 4 m-thick sections were cut at 150-m step-sections and stained with hematoxylin and eosin at the St. Jude Histology Core Facility. An average of 90 -100 islets per mouse were scored in a blinded manner using the following metric: no insulitis (normal islet and no infiltration), periinsulitis (infiltration on edges of islet or 0 -20% of islet infiltrated) or insulitis (infiltration of 30 -100% of islet). Statistics. The time to diabetes (survivor function) for each group of mice was estimated using the Kaplan-Meier log-rank test both overall and pairwise within each experiment. The overall Type I error rate for each experiment was controlled at the 0.05 level using the Bonferroni adjustment for multiple comparisons.
RESULTS
Cloning and expression of ␤-cell-specific TCRs. GAD65 is one of the principal autoantigens in human type 1 diabetes and was one of the first autoantigens implicated in diabetes in NOD mice (10, 11) . Nevertheless, its role as a target autoantigen remains controversial (24, 26, 33, 34) . We cloned and expressed seven different TCRs specific for the major immunogenic GAD epitopes and others that have been proposed to modulate disease progression (Table 1) (35, 36) . All of the GAD-specific TCRs, with the exception of 1A4, were derived by immunizing NOD mice with peptide. 1A4 was isolated from the islets of a nonimmunized, nondiabetic NOD mouse. Four different TCRs based on relevant epitope immunogenicity were chosen: PA15.14B12 and PA19.5E11 (specific for GAD 206 -220 , the primary immunogenic epitope of GAD65) and 1A4 and PA17.9G7 (which covered the second and third most immunogenic epitopes GAD 221-235 and GAD 284 -300 , respectively) (35, 36) . We also cloned and expressed three differ- The data are represented as peri-insulitis/insulitis at 28, 70, or 140 days posttransplant. §Incidence of diabetes. ¶Number of days posttransplant that 50% of the mice that became diabetic had a blood glucose level Ͼ400mg/dl. ʈThe 12-4.4 sequence used in this study was reconstructed from information obtained from the study by Wegmann et al. (15) . However, as a result of changes in J␣ nomenclature since publication of their article, an alternate J␣ was used in its construction (a modified J␣42 ͓SGGSNYKLTFGKGTKLSVKS͔ rather than J␣53 ͓SGGSNYKLTFGKGTLLTVTP͔). It is important to note that 12-4.4v1 retains insulin reactivity and mediates significant islet infiltration and thus represents a very useful research reagent. As this is now a variant of the original 12-4.4, we refer to this TCR as 12-4.4v1. **Not applicable (NA) because the peptide specificity of the TCR is not known. The inapplicable TCRs were activated with whole islets to determine functionality. † †Not applicable because the mice were all diabetic by 70 and 140 days posttransplant. ND, not determined. Fig. 2 for a mean of all mice examined) .
ent TCRs specific for the COOH-terminus portion of GAD65 thought to be important in the initiation of islet infiltration and ␤-cell destruction, two of which-PA18.9H7 and 530.45.19 -cover the GAD 524 -538 and GAD 530 -543 epitope, respectively, and PA18.10F10, specific for GAD 510 -524 , just upstream of epitope GAD 524 -543 (Table  1) . 530.45.19 and PA18.9H7 are particularly intriguing because it has been reported that spontaneously arising, GAD-reactive T-cells in NOD mice use V␤4 ϩ (530.45.19) and are specific for the 530 -543 epitope, while TCRs that recognize GAD 524 -538 are primarily generated by immunization, use V␤12 (PA18.9H7) and may have regulatory activity (10,13,34 ).
Insulin has also been implicated in the diabetogenic response. A considerable number of T-cells infiltrating the islets react to insulin, with Ͼ90% recognizing the insulin B 9 -23 epitope (15, 37) . Recently it has been shown that insulin I/II null NOD mice expressing an insulin transgene with a mutation in the critical insulin B 9 -23 epitope did not develop disease, suggesting that it is a primary autoantigenic epitope (38) . T-cell clones generated against insulin B 9 -23 both accelerate diabetes onset in NOD mice and confer disease following adoptive transfer into NOD.scid mice (15) . The 12-4.1 and 12-4.4
v1 TCRs were originally isolated from the islets of prediabetic NOD mice and were reconstructed by PCR from published sequences (see RESEARCH DESIGN AND METHODS and Table 1 for details) and expressed in NOD.scid mice.
Insulinoma-associated tyrosine phosphatase-like protein (IA2) or islet cell antigen 512 is found in the secretory granules of ␤-cells (17, 39) and is a potential target of CD4 ϩ T-cells (16, 18, 40) . We cloned the TCR 10.23, which is specific for IA2 and was derived through immunizations with whole protein. We later identified the epitope as IA2 676 -688 (data not shown). In addition, given the implication of IA2␤ (phogrin)-reactive CD4
ϩ T-cells in disease pathogenesis (19, 20, 41) , two phogrin-specific TCRs, phogrin13 and phogrin18, were cloned from T-cell lines established by immunization with whole protein (41) .
Included in this study were clonotypic BDC-2.5, BDC-6.9, BDC-10.1, and NY4.1 TCRs specific for undefined ␤-cell epitopes. BDC-2.5, BDC-6.9, and BDC-10.1 were the first diabetogenic CD4
ϩ T-cell clones described and were originally isolated from the spleen and lymph nodes of diabetic NOD mice by Haskins and colleagues (8, 42, 43) , while NY4.1 was one of six CD4 ϩ T-cell clones that were isolated from the islets of acutely diabetic NOD mice and were reactive to islet cells (44) . These clones are highly diabetogenic upon transfer into NOD.scid mice or when expressed as a transgene in NOD mice (BDC-2.5, BDC-6.9, and NY4.1) (21) (22) (23) 45, 46) . We have previously generated BDC-2.5 and NY4.1 Rg mice (26) , which were included in this study as positive controls for the other TCR Rg mice. Likewise, Rg mice expressing PA21.14H4, an H-2A g7 -restricted, HEL 11-25 -specific TCR, were included as negative controls.
TCR Rg mice were established using NOD.scid mice as both bone marrow donors and recipients. This enabled us to examine the ability of Rg T-cells to infiltrate the islets and mediate diabetes in the absence of other T-cells or B-cells. For each TCR, we examined expression and reconstitution levels, T-cell proliferative capacity, and the incidence of insulitis and diabetes in the Rg mice. Expression and function of ␤-cell-specific TCRs. All of the TCRs were expressed in mice and had comparable levels of GFP ( Fig. 1 and data not shown) . However, there was variability in TCR expression levels compared with the NOD control and in the number of GFP ϩ /TCR ϩ /CD4 ϩ Rg T-cells in the spleen, ILN, and PLN ( Figs. 1 and 2 ). This is likely due to the influence of thymic selection and the availability of selecting ligands, as well as homeostatic and antigen-driven proliferation in the periphery. Importantly, TCR expression level and T-cell numbers were consistent within each group, suggesting that this variability was due to intrinsic characteristics of each TCR rather then experimental variance. Also, there was a correlation between the number of T-cells in the spleen compared with the ILN and PLN within each TCR Rg group (Fig. 2) . The GAD65-specific TCRs were reactive to and specific 
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for their respective peptides, albeit with differing efficiencies (Table 1 and Fig. 3A and B) . While 12-4.1 and 12-4.4 v1 recognize the same epitope (insulin B 9 -23 ), the significant difference in stimulation index observed is likely due to differences in cognate ligand affinity caused by differences in complimentarity-determining region/V␤ usage (Table 1) . Furthermore, differences in IA2-and phogrin-specific TCR expression in 10.23, phogrin13, and phogrin18 Rg mice may explain the differing reactivity observed (Table 1 and Figs. 1 and 3A) . However, Rg T-cells were antigen specific and T-cells isolated from the spleen and PLN reacted equivalently, as exemplified with phogrin18 T-cells (Fig.  3C and data not shown) . Finally, all of the unknown islet antigen-specific TCRs-BDC-2.5, BDC-6.9, BDC-10.1, and NY4.1-were expressed at detectable levels (Fig. 1) . The level of TCR expression was more variable among some of the Rg mice. This was particularly evident with BDC-2.5 T-cells and may, in part, be due to the relatively low level of TCR expression seen in these mice compared with other Rg T-cells (Figs. 1 and 2 ). The functionality of these Rg T-cells was determined by measuring proliferation in response to purified, irradiated islets from 11-to 19-weekold NOD mice. BDC-10.1 Rg T-cells were strongly reactive to irradiated islets, while BDC-2.5 T-cells responded weakly compared with the control HEL-specific PA21.14H4 Rg T-cells, Rg T-cells alone, and islets alone (Fig. 3D and data not shown) . In contrast, minimal reactivity was seen with BDC-6.9 and NY4.1 Rg T-cells, suggesting that either these islets express insufficient levels of the antigenic epitope to elicit proliferation in vitro or, more likely, that T-cells derived from these Rg mice are less sensitive than the parent T-cell clones.
Insulitis and incidence of diabetes of Rg mice. Next, we evaluated the extent of insulitis 28, 70, and/or 140 days post-bone marrow transplant and the incidence of diabetes for 140 days in the 17 TCR Rg mouse lines. Essentially, no peri-insulitis or insulitis was observed in any of the GAD-specific Rg mice (Table 1 and Fig. 4) . Likewise, minimal infiltration of IA2 676 -688 -specific 10.23 T-cells or IA2␤/phogrin 640 -659 -specific phogrin13 T-cells was seen in the respective Rg mice. This was surprising because the phogrin-specific T-cell clones phogrin15 and phogrin12 infiltrate rat islets transplanted under the kidney capsule and destroy ␤-cells (41) . However, demonstrable periinsulitis (ϳ11%) and insulitis (ϳ6%) were observed in IA2␤/phogrin 755-777 -specific phogrin18 Rg mice, although this was not manifested until 140 days posttransfer (Table  1 and Fig. 4) . The differential ability of these phogrinspecific T-cells to infiltrate islets may be due to differences in epitope recognition or TCR affinity/avidity (Table 1) . Not surprisingly, none of these Rg mice developed diabetes (Table 1) .
Analysis of the two insulin B 9 -23 Rg mice was particularly intriguing. While significant peri-insulitis and insulitis were observed, insulitis was greater in the 12-4.1 versus the 12-4.4 v1 Rg mice (Table 1) . Furthermore, diabetes developed in 33% of the 12-4.1 Rg mice (ID 50 -60 days), while none of the 12-4.4 v1 Rg mice became diabetic. The difference in diabetes incidence may be due to differences in the relative avidity of the corresponding T-cells to antigen ( Table 1 ). The peri-insulitis/insulitis score appeared to decline by 140 days posttransfer. Given that a proportion of the 12-4.1 Rg mice becomes diabetic, it is possible that this reduced insulitis score is due to the reduced disease incidence in the remaining mice. However, this cannot account for the decline in the 12-4.4
v1 Rg mice and suggests that the insulitis resolves with time in these mice.
As previously reported, BDC-2.5 and NY4.1 Rg mice developed significant insulitis ϳ28 days posttransfer, which is remarkable given that it takes ϳ50 days for complete bone marrow reconstitution and maximal T-cell population of the periphery. There was also substantial insulitis in the BDC-10.1 Rg mice (87% for BDC-10.1 vs. 93% for BDC-2.5 at 28 days posttransfer [ Table 1 and Fig. 4]) . Indeed, there was a correlation between the percentage of infiltrating CD4
ϩ Rg T-cells and the severity of insulitis and incidence of diabetes (BDC-10.1, 5.9% CD4 ϩ T-cells in the islets; BDC-2.5, 5.1%; 12-4.1, 3.6%; phogrin18, 0.6%; and PA21.14H4, 0.2%).
Diabetes incidence in the BDC-2.5 Rg mice was 100% with an ID 50 of 52 days. Curiously, the rate of diabetes development in the NY4.1 Rg mice was comparable (ID 50 -46 days) but the incidence was only 71% (Table 1 and Fig.  5A ). Insulitis development in the BDC-6.9 Rg mice was delayed, with no insulitis at day 28 but substantial insulitis at days 70 and 140 posttransfer. Consistent with this, diabetes onset in the BDC-6.9 Rg mice was delayed (ID 50 -81 days; incidence -56%), in accordance with observations made with their Tg counterparts (22) . Diabetes onset in the BDC-10.1 Rg mice was rapid and highly penetrant with all the mice hyperglycemic by day 33 (ID 50 -27 days) (Fig.  5A) . Given the diabetogenic potential of the BDC-10.1 TCR and the flexibility of the Rg system, BDC-10.1 Rg T-cells were generated on a C57BL/6 background using the B6g7.RAG-1 Ϫ/Ϫ mice. Interestingly, BDC-10.1 Rg T-cells on a nonautoimmune background mediated diabetes, albeit at a slower rate (ID 50 Ϫ 76 days) and reduced frequency (80%) (Fig. 5A) .
To further evaluate the diabetogenic potency of the BDC-10.1 Rg T-cells, GFP ϩ
CD4
ϩ T-cells were sorted from BDC-10.1, NY4.1, and the control TCR PA21.14H4 Rg mice and adoptively transferred into NOD.scid mice (Fig. 5B) . As expected, the HEL-specific T-cell recipients failed to develop diabetes, while mice receiving NY4.1 Rg T-cells initially developed diabetes by day 55 posttransfer, and by day 138 all recipients were diabetic. Strikingly, all of the BDC-10.1 T-cell recipients developed diabetes by day 13 posttransfer. Finally, we adoptively transferred titrated numbers of purified BDC-10.1 Rg T-cells into NOD.scid mice to define the minimal number required to mediate disease (Fig. 5C) . Remarkably, only 50,000 BDC-10.1 Rg T-cells were required to cause rapid diabetes onset in 100% of recipients by day 13, while as few as 1,000 BDC-10.1 Rg T-cells caused diabetes in 80% of recipients. Taken together, these data highlight the increased diabetogenic potential of BDC-10.1 T-cells.
DISCUSSION
Type 1 diabetes is a complex disease mediated by T-cells of multiple specificities, many of which have yet to be determined. Important questions remain concerning what governs T-cell islet entry, what makes a T-cell diabetogenic, and what the relationship is between autoreactivity and pathogenicity. While the generation of TCR Tg mice has provided important insight into the disease process, these studies represent a limited repertoire of potential autoantigen epitope-specific TCRs that might mediate type 1 diabetes. Our study demonstrates the utility of the Rg approach for the generation and analysis of mice expressing a large panel of TCRs with varied specificity. These data show that for the panel of TCRs studied, relatively few promote islet entry and ␤-cell destruction in the absence of other T-cells and B-cells. Indeed, it is noteworthy that four of the five TCRs that promoted diabetes when expressed in Rg mice recognize unknown antigens.
It has recently been suggested that GAD-reactive T-cells may not be as critical to the initiation and progression of type 1 diabetes as originally thought (10, 11, 33) . Our data support this view. Despite the high immunogenicity of GAD epitopes (206 -220, 221-235 and 284 -300) and the large number of Rg T-cells in the spleens and lymph nodes, no ␤-cell destruction was seen in the seven GAD-reactive TCR Rg mouse lines analyzed. While some peri-insulitis was observed in some mice, particularly those expressing TCR specific for distal GAD epitopes (e.g., 530.45.19 specific for GAD 530 -543 ), this was not significantly greater compared with HEL-specific Rg mice (PA21.14H4). While we cannot rule out a role for GAD-reactive T-cells in the later stages of pathogenesis or in concert with other T-cells (34) , our data suggest that T-cells expressing the current panel of clonotypic TCRs specific for GAD are not capable of initiating insulitis and diabetes on their own. Furthermore, several studies suggest that certain GADreactive TCRs are expressed by regulatory T-cells, an issue that was not addressed in this study. While the IA2-specific Rg T-cells did not infiltrate the islets, suggesting that IA2 may not be an important autoantigenic epitope in the early stages of type 1 diabetes, both phogrin-specific T-cell populations infiltrated islets to varying degrees. However, although phogrin18 mediated significant peri-insulitis/insulitis, likely due to increased TCR expression and T-cell number, this required 140 days to develop. Taken together, these data suggest that some of the most commonly studied type 1 diabetes autoantigens-GAD, IA2 and IA2␤/ phogrin-may have a reduced role in initiating type 1 diabetes.
On the other hand, the importance of insulin as an autoantigen (38, 47) was reaffirmed in this study. Both insulin-specific TCRs conferred significant insulitis, while only 12-4.1 caused diabetes. Given that these TCRs recognize the same epitope, the phenotypic distinctions observed are likely due to differences in TCR V␤ (V␤2 vs. V␤12) and complimentarity-determining region usage, and/or affinity/avidity as the 12-4.1 Rg T-cells have a considerably higher stimulation index against the insulin B 9 -23 epitope. This suggests that while autoantigen and epitope availability are important factors in mediating the disease process, TCR affinity is likely an important factor.
Differences in the diabetogenicity of TCRs from BDC-2.5, BDC-6.9, and BDC-10.1 in Rg mice would not have been predicted from their pathogenicity as T-cell clones, which is very similar in adoptive transfers into young NOD or NOD.scid recipients (8, 43) . The hierarchy of insulitic and diabetogenic potential exhibited by the three TCRs that had previously been expressed as transgenes was largely as expected (BDC-2.5 Ͼ NY4.1 Ͼ BDC-6.9) (21-23). The most surprising observation was the diabetogenic potential of Rg T-cells expressing the BDC-10.1 TCR. These data suggest that this TCR may recognize a critical epitope in disease etiology and/or may have an optimal affinity/avidity for maximal islet infiltration and ␤-cell destruction. It is important to note that despite the autoreactivity of BDC-2.5, BDC-10.1, and NY4.1, all three TCRs were expressed, and Rg T-cells escaped thymic selection (albeit to a lesser extent in the spleen compared with other Rg T-cells). This suggests that diabetogenicity was attributed to the specificity of the TCR and not to differences in the levels of TCR expression or the number of Rg T-cell present in mice.
Taken together, these data suggest that autoantigenspecific TCRs can be segregated into three phenotypic groups: 1) TCRs that fail to mediate T-cell islet entry but may play a role in the later stages of the disease (e.g., TCRs specific for GAD and IA2), 2) TCRs that mediate islet infiltration but not ␤-cell destruction and thus may only contribute significantly to type 1 diabetes if potentiated by diabetogenic T-cells (e.g., certain phogrin-and insulinspecific TCRs), and 3) TCRs that mediate (to varying degrees) insulitis and ␤-cell destruction and thus may be key initiators/propagators of type 1 diabetes (e.g., certain TCRs specific for insulin and unknown islet antigens). Understanding the molecular distinctions between these three populations will be critically important. In addition, gaining insight into the levels and timing of autoantigen expression/availability as well as the location/phenotype of the APCs presenting autoantigens will be important and may explain the differences we observed between the autoreactive Rg T-cells. In conclusion, our data suggest that autoreactivity does not imply pathogenicity, as most autoreactive TCRs, on their own, appear to be nonpathogenic.
